Efficacy and safety of Armolipid Plus®: an updated PRISMA compliant systematic review and meta-analysis of randomized controlled clinical trials
| Autor: | Marilisa Bove, Arrigo F G Cicero, Coralie M.G. Georges, Tamara Knežević, Federica Fogacci, Agnė Šatrauskienė, Cormac Kennedy, Peter P. Toth |
|---|---|
| Přispěvatelé: | Cicero AF, Kennedy C, Knežević T, Bove M, Georges CMG, Šatrauskienė A, Toth PP, Fogacci F., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Armolipid Plus® supplementation armolipid Plus® berberine blood pressure fasting plasma glucose lipids nutraceutical red yeast rice Blood lipids lcsh:TX341-641 030204 cardiovascular system & hematology Gastroenterology Article Mean difference Body Mass Index 03 medical and health sciences 0302 clinical medicine lipid Internal medicine medicine Humans Dietary supplementation 030212 general & internal medicine Lipoprotein cholesterol Nutrition and Dietetics biology business.industry C-reactive protein Lipid Metabolism Clinical trial Meta-analysis Dietary Supplements biology.protein business Body mass index lcsh:Nutrition. Foods and food supply Food Science |
| Zdroj: | Nutrients, Vol 13, Iss 638, p 638 (2021) Nutrients Volume 13 Issue 2 Nutrients, Vol. 13, no.2, p. 638 [1-17] (2021) Nutrents, Basel : MDPI, 2021, vol. 13, no. 2, art. no. 638, p. [1-17] |
| ISSN: | 2072-6643 |
| Popis: | Armolipid Plus® is a multi-constituent nutraceutical that claims to improve lipid profiles. The aim of this PRISMA compliant systematic review and meta-analysis was to globally evaluate the efficacy and safety of Armolipid Plus® on the basis of the available randomized, blinded, controlled clinical trials (RCTs). A systematic literature search in several databases was conducted in order to identify RCTs assessing the efficacy and safety of dietary supplementation with Armolipid Plus®. Two review authors independently identified 12 eligible studies (1050 included subjects overall) and extracted data on study characteristics, methods, and outcomes. Meta-analysis of the data suggested that dietary supplementation with Armolipid Plus® exerted a significant effect on body mass index (mean difference (MD) = −0.25 kg/m2, p = 0.008) and serum levels of total cholesterol (MD = −25.07 mg/dL, p < 0.001), triglycerides (MD = −11.47 mg/dL, p < 0.001), high-density lipoprotein cholesterol (MD = 1.84 mg/dL, p < 0.001), low-density lipoprotein cholesterol (MD = −26.67 mg/dL, p < 0.001), high sensitivity C reactive protein (hs-CRP, MD = −0.61 mg/L, p = 0.022), and fasting glucose (MD = −3.52 mg/dL, p < 0.001). Armolipid Plus® was well tolerated. This meta-analysis demonstrates that dietary supplementation with Armolipid Plus® is associated with clinically meaningful improvements in serum lipids, glucose, and hs-CRP. These changes are consistent with improved cardiometabolic health. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|